Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Invivyd
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
April 15, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces CEO Transition
April 12, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
April 04, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
March 28, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
March 22, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
March 22, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
January 03, 2024
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
December 18, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
November 02, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Participate in Upcoming Investor Conferences
October 31, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
September 11, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Participate in Upcoming Investor Conferences
September 06, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Appoints William Duke as Chief Financial Officer
September 05, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights
August 10, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Appointment of Sara Cotter to Board Of Directors
July 27, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
July 17, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19
June 26, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
June 22, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Participate at the Jefferies Healthcare Conference
June 01, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
May 11, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
May 04, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
April 25, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update
April 25, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer
April 12, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19
March 30, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Reports Full Year 2022 Financial Results and Business Highlights
March 23, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19
March 22, 2023
From
Invivyd
Via
GlobeNewswire
Tickers
IVVD
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.